$2.00
1.52% today
NYSE, Feb 28, 05:22 pm CET
ISIN
US67080N1019
Symbol
NUVB
Sector
Industry

Nuvation Bio Inc - Ordinary Shares - Class A Stock price

$1.97
-0.53 21.20% 1M
-1.11 36.04% 6M
-0.69 25.94% YTD
-0.02 1.01% 1Y
-3.09 61.07% 3Y
-8.03 80.30% 5Y
-8.03 80.30% 10Y
NYSE, Closing price Thu, Feb 27 2025
-0.01 0.51%
ISIN
US67080N1019
Symbol
NUVB
Sector
Industry

Key metrics

Market capitalization $665.01m
Enterprise Value $127.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 58.82
P/S ratio (TTM) P/S ratio 307.88
P/B ratio (TTM) P/B ratio 1.32
Revenue (TTM) Revenue $2.16m
EBIT (operating result TTM) EBIT $-134.45m
Free Cash Flow (TTM) Free Cash Flow $-99.33m
Cash position $549.14m
EPS (TTM) EPS $-2.17
P/E forward negative
P/S forward 305.44
EV/Sales forward 58.36
Short interest 10.51%
Show more

Is Nuvation Bio Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Nuvation Bio Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Nuvation Bio Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.16 2.16
-
100%
- Direct Costs 3.38 3.38
1,308% 1,308%
156%
-1.22 -1.22
408% 408%
-56%
- Selling and Administrative Expenses 48 48
58% 58%
2,201%
- Research and Development Expense 85 85
17% 17%
3,943%
-134 -134
30% 30%
-6,200%
- Depreciation and Amortization 0.52 0.52
117% 117%
24%
EBIT (Operating Income) EBIT -134 -134
30% 30%
-6,224%
Net Profit -532 -532
542% 542%
-24,643%

In millions USD.

Don't miss a Thing! We will send you all news about Nuvation Bio Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvation Bio Inc - Ordinary Shares - Class A Stock News

Neutral
Business Wire
4 days ago
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA. A live webcast of the p...
Neutral
PRNewsWire
10 days ago
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.
Positive
Seeking Alpha
15 days ago
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~...
More Nuvation Bio Inc - Ordinary Shares - Class A News

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Head office United States
CEO David Hung
Employees 51
Founded 2018
Website www.nuvationbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today